Share-based Payment Arrangement, Expense of Unity Biotechnology, Inc. from 31 Dec 2016 to 31 Mar 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Unity Biotechnology, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2016 to 31 Mar 2025.
  • Unity Biotechnology, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2025 was $617,000, a 56% decline year-over-year.
  • Unity Biotechnology, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2025 was $3,193,000, a 52% decline year-over-year.
  • Unity Biotechnology, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $3,970,000, a 46% decline from 2023.
  • Unity Biotechnology, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,419,000, a 21% decline from 2022.
  • Unity Biotechnology, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $9,379,000, a 19% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Unity Biotechnology, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2025 $3,193,000 $617,000 -$777,000 -56% 01 Jan 2025 31 Mar 2025 10-Q 22 Apr 2025 2025 Q1
Q4 2024 $3,970,000 $805,000 -$487,000 -38% 01 Oct 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
Q3 2024 $4,457,000 $797,000 -$908,000 -53% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2024 2024 Q3
Q2 2024 $5,365,000 $974,000 -$1,273,000 -57% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2024 2024 Q2
Q1 2024 $6,638,000 $1,394,000 -$781,000 -36% 01 Jan 2024 31 Mar 2024 10-Q 22 Apr 2025 2025 Q1
Q4 2023 $7,419,000 $1,292,000 -$967,000 -43% 01 Oct 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
Q3 2023 $8,386,000 $1,705,000 -$505,000 -23% 01 Jul 2023 30 Sep 2023 10-Q 04 Nov 2024 2024 Q3
Q2 2023 $8,891,000 $2,247,000 -$3,000 -0.13% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $8,894,000 $2,175,000 -$485,000 -18% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $9,379,000 $2,259,000 -$682,000 -23% 01 Oct 2022 31 Dec 2022 10-K 07 Mar 2025 2024 FY
Q3 2022 $10,061,000 $2,210,000 -$876,000 -28% 01 Jul 2022 30 Sep 2022 10-Q 13 Nov 2023 2023 Q3
Q2 2022 $10,937,000 $2,250,000 -$532,000 -19% 01 Apr 2022 30 Jun 2022 10-Q 08 Aug 2023 2023 Q2
Q1 2022 $11,469,000 $2,660,000 -$84,000 -3.1% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $11,553,000 $2,941,000 +$241,000 +8.9% 01 Oct 2021 31 Dec 2021 10-K 15 Apr 2024 2023 FY
Q3 2021 $11,312,000 $3,086,000 -$606,000 -16% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $11,918,000 $2,782,000 -$1,322,000 -32% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2022 2022 Q2
Q1 2021 $13,240,000 $2,744,000 -$573,000 -17% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $13,813,000 $2,700,000 -$388,000 -13% 01 Oct 2020 31 Dec 2020 10-K 15 Mar 2023 2022 FY
Q3 2020 $14,201,000 $3,692,000 -$131,000 -3.4% 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $14,332,000 $4,104,000 +$2,160,000 +111% 01 Apr 2020 30 Jun 2020 10-Q 10 Aug 2021 2021 Q2
Q1 2020 $12,172,000 $3,317,000 +$1,320,000 +66% 01 Jan 2020 31 Mar 2020 10-Q 11 May 2021 2021 Q1
Q4 2019 $10,852,000 $3,088,000 +$572,000 +23% 01 Oct 2019 31 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $10,280,000 $3,823,000 +$1,106,000 +41% 01 Jul 2019 30 Sep 2019 10-Q 04 Nov 2020 2020 Q3
Q2 2019 $9,174,000 $1,944,000 -$894,000 -32% 01 Apr 2019 30 Jun 2019 10-Q 31 Jul 2020 2020 Q2
Q1 2019 $10,068,000 $1,997,000 +$627,000 +46% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q4 2018 $9,441,000 $2,516,000 +$979,000 +64% 01 Oct 2018 31 Dec 2018 10-K 23 Mar 2021 2020 FY
Q3 2018 $8,462,000 $2,717,000 +$2,158,000 +386% 01 Jul 2018 30 Sep 2018 10-Q 06 Nov 2019 2019 Q3
Q2 2018 $6,304,000 $2,838,000 +$2,313,000 +441% 01 Apr 2018 30 Jun 2018 10-Q 07 Aug 2019 2019 Q2
Q1 2018 $3,991,000 $1,370,000 +$957,000 +232% 01 Jan 2018 31 Mar 2018 10-Q 08 May 2019 2019 Q1
Q4 2017 $3,034,000 $1,537,000 01 Oct 2017 31 Dec 2017 10-K 11 Mar 2020 2019 FY
Q3 2017 $559,000 01 Jul 2017 30 Sep 2017 10-Q 07 Nov 2018 2018 Q3
Q2 2017 $525,000 01 Apr 2017 30 Jun 2017 10-Q 09 Aug 2018 2018 Q2
Q1 2017 $413,000 01 Jan 2017 31 Mar 2017 10-Q 07 Jun 2018 2018 Q1

Unity Biotechnology, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $3,970,000 -$3,449,000 -46% 01 Jan 2024 31 Dec 2024 10-K 07 Mar 2025 2024 FY
2023 $7,419,000 -$1,960,000 -21% 01 Jan 2023 31 Dec 2023 10-K 07 Mar 2025 2024 FY
2022 $9,379,000 -$2,174,000 -19% 01 Jan 2022 31 Dec 2022 10-K 07 Mar 2025 2024 FY
2021 $11,553,000 -$2,260,000 -16% 01 Jan 2021 31 Dec 2021 10-K 15 Apr 2024 2023 FY
2020 $13,813,000 +$2,961,000 +27% 01 Jan 2020 31 Dec 2020 10-K 15 Mar 2023 2022 FY
2019 $10,852,000 +$1,411,000 +15% 01 Jan 2019 31 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $9,441,000 +$6,407,000 +211% 01 Jan 2018 31 Dec 2018 10-K 23 Mar 2021 2020 FY
2017 $3,034,000 +$2,810,000 +1254% 01 Jan 2017 31 Dec 2017 10-K 11 Mar 2020 2019 FY
2016 $224,000 01 Jan 2016 31 Dec 2016 10-K 06 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.